The use of intraperitoneal chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit over intravenous chemotherapy.
Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
Despite achieving complete surgical resection, advanced epithelial ovarian cancer or primary peritoneal cancer patients with a high disease burden had worse survival outcomes than those with lower disease burden.
Could the approval of bevacizumab for advanced cervical cancer and platinum-resistant ovarian cancer last year lead to patient-specific therapies?
Adding the PARP inhibitor veliparib to cyclophosphamide did not improve response rates or progression-free survival in ovarian cancer.
ACOG recently released a Committee Opinion on the use of salpingectomy for ovarian cancer prevention in at-risk women undergoing routine pelvic surgery.
The FDA has approved olaparib, to be marketed under the name Lynparza, for the treatment of advanced ovarian cancer related to defective BRCA genes.
Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.
Ovarian cancer cells were detected by collecting and testing DNA specimens taken from the tampons of ovarian cancer patients prior to surgery for a pelvic mass.